Am­neal touts re­sults from Phase III tri­al in Parkin­son's; No­vaRock part­ners on can­cer drug

Am­neal Phar­ma­ceu­ti­cals an­nounced pos­i­tive re­sults yes­ter­day from a piv­otal Phase III clin­i­cal tri­al that eval­u­at­ed IPX-203 in pa­tients with Parkin­son’s dis­ease who have mo­tor fluc­tu­a­tions.

The tri­al met its pri­ma­ry end­point, demon­strat­ing su­pe­ri­or “Good On” time — time with­out dysk­i­ne­sia — from base­line in hours per day at the end of the 13-week dou­ble-blind­ed treat­ment pe­ri­od with IPX-203, an ex­tend­ed-re­lease for­mu­la­tion of car­bidopa/lev­odopa. The drug da­ta was com­pared with im­me­di­ate-re­lease car­bidopa/lev­odopa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER